Prelude Capital Management’s Protara Therapeutics TARA Stock Holding History

Prelude Capital Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,516	Closed	-$93.6K	–	1547
2025 Q3	$93.6K	Sell	21,516 -1,300	-6%	-$4.21K	0.01%	1062
2025 Q2	$69.1K	Buy	+22,816	New	+$78.7K	0.01%	944
2022 Q2	–	Sell	-12,872	Closed	-$66K	–	2052
2022 Q1	$66K	Sell	12,872 -3,983	-24%	-$20.9K	﹤0.01%	1469
2021 Q4	$114K	Buy	16,855 +3,700	+28%	+$25.5K	﹤0.01%	1690
2021 Q3	$91K	Buy	13,155 +1,455	+12%	+$11.3K	﹤0.01%	1516
2021 Q2	$114K	Buy	+11,700	New	+$133K	﹤0.01%	1448
2018 Q1	–	Sell	-124	Closed	-$9K	–	1713
2017 Q4	$9K	Buy	+124	New	+$9.94K	﹤0.01%	1218

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Prelude Capital Management's TARA Position: Q4 2025 in Review

Prelude Capital Management sold out of Protara Therapeutics (TARA) in Q4 2025, closing a stake of 21,516 shares — an estimated $93.6K sold.

Prelude Capital Management first reported a position in TARA in Q4 2017 and held it in 7 quarters. The position peaked at $114K in Q4 2021. 105 funds tracked by Wall St. Rank hold TARA as of Q4 2025.

Prelude Capital Management reported no remaining Protara Therapeutics position as of Q4 2025 after selling out during the quarter.
Prelude Capital Management sold 21,516 Protara Therapeutics shares in Q4 2025, an estimated $93.6K.
Prelude Capital Management first reported a position in Protara Therapeutics in Q4 2017 and held it in 7 quarters.
Prelude Capital Management's Protara Therapeutics position peaked at $114K in Q4 2021.
105 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.